APA (7th ed.) Citation

M, M., E, C., Á, R., R, A., S, S., A, A., . . . D, A. (2023). Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry. Breast cancer research and treatment, 201(2), 151. https://doi.org/10.1007/s10549-023-07002-1

Chicago Style (17th ed.) Citation

M, Martín, et al. "Long-term Outcomes of High-risk HR-positive and HER2-negative Early Breast Cancer Patients from GEICAM Adjuvant Studies and El Álamo IV Registry." Breast Cancer Research and Treatment 201, no. 2 (2023): 151. https://doi.org/10.1007/s10549-023-07002-1.

MLA (9th ed.) Citation

M, Martín, et al. "Long-term Outcomes of High-risk HR-positive and HER2-negative Early Breast Cancer Patients from GEICAM Adjuvant Studies and El Álamo IV Registry." Breast Cancer Research and Treatment, vol. 201, no. 2, 2023, p. 151, https://doi.org/10.1007/s10549-023-07002-1.